VINC Projected Dividend Yield
Vincerx Pharma Inc ( NASDAQ : VINC )Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company. Co. is focused on developing differentiated and novel therapies to address the unmet medical needs of patients with cancer. It has a next generation bioconjugation platform, called VersAptx. The VersAptx platform is a versatile and adaptable, next generation bioconjugation platform. Its product candidates include VIP943 (CD123-KSPi), VIP924 (CXCR5-KSPi), VIP236, and Enitociclib (P-TEFb/CDK9 inhibitor). VIP943 is a potential anti-CD123 ADC created with its VersAptx Platform. It consists of an anti-CD123 antibody, a novel legumain-cleavable linker, and a KSPi payload enhanced with its CellTrapper technology. 20 YEAR PERFORMANCE RESULTS |
VINC Dividend History Detail VINC Dividend News VINC Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |